Loading data for SCNI — first visit, this takes a few seconds.
Scinai Immunotherapeutics Ltd.
0.75 +0.00 (0.00%)
- Market Cap
- $1.01M
- Volume
- 109K
- Dividend yield
- 0.00%
- Next earnings date
- Nov 9, 2015
Scinai Immunotherapeutics Ltd. (SCNI) Stock Price, Analysis & Data
Intrinsic value
See plans →Analyst Forecast
Stock Forecasts →You're seeing the free overview
Create a free account to explore more research on this ticker.
Latest Earnings
| Reported | Vs estimate | YoY Change | |
|---|---|---|---|
| Revenue | $460.0K | n/a | n/a |
| EPS | -$24.00 | -$17.80 | -8375.86% |
Metrics
- Bid
- 0.66
- Market Cap
- 1.01M
- Revenue (ttm)
- 1.49M
- Net Income (ttm)
- -2.6M
- 2.13
- 28.07
- 0.03
- n/a
- P/B (ttm)
- 0.07
- P/S (ttm)
- 0.68
- Earnings Date
- Nov 9, 2015
- Ask
- 0.87
- Volume
- 109,082
- Avg. Volume (20D)
- 2,142,009
- Open
- 0.75
- Previous Close
- 0.75
- Day's Range
- 0.66 - 0.75
- 52-Week Range
- 0.66 - 15.50
- Analyst
- n/a
- Price Target
- n/a
- Dividends
- n/a
- Ex-Dividend Date
- n/a
About Scinai Immunotherapeutics Ltd.
View profile →Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract development and manufacturing organization services, such as analytical method development, process development, and cGMP manufacturing of clinical-stage materials to early-stage biotechnology companies. It has collaboration partnerships with Max Planck Society and University Medical Center Gottingen for the development of NanoAb candidates; and Recipharm Israel Ltd for the development of biologics and small-molecule programs. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is based in Jerusalem, Israel.
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract development and manufacturing organization services, such as analytical method development, process development, and cGMP manufacturing of clinical-stage materials to early-stage biotechnology companies. It has collaboration partnerships with Max Planck Society and University Medical Center Gottingen for the development of NanoAb candidates; and Recipharm Israel Ltd for the development of biologics and small-molecule programs. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is based in Jerusalem, Israel.
Industry Biotechnology
Sector Healthcare
IPO Date May 11, 2015
Employees 45
Stock Exchange NasdaqCM
Ticker Symbol SCNI
Website https://www.scinai.com